Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Research of the Correlation Between Metabolic Syndrome, Retinal Thickness and Visual Acuity

This study has been completed.
Sponsor:
Information provided by:
Taipei Medical University WanFang Hospital
ClinicalTrials.gov Identifier:
NCT01219478
First received: October 10, 2010
Last updated: December 19, 2010
Last verified: December 2010
  Purpose

Purpose: To investigate the relationship between retinal thickness (RT) and metabolic risks (MRs) in patients without retinal lesion.

Methods: Fifty-two patients over 60 y/o were divided into four groups according to their MRs of hypertension, hyperlipidemia or hyperglyceremia. After complete ophthalmic examination, optical coherence tomography was performed to measure RT.


Condition
Visual Acuity

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Research of the Correlation Between Metabolic Syndrome, Retinal Thickness and Visual Acuity

Resource links provided by NLM:


Further study details as provided by Taipei Medical University WanFang Hospital:

Enrollment: 100
Study Start Date: January 2009
Study Completion Date: December 2009
Groups/Cohorts
control
0 metabloil risk
1
1 metabloil risk
2
2 metabloil risk
3
3 metabloil risk

  Eligibility

Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients who were over 60 y/o were divided into four groups according to their MRs of hypertension, hyperlipidemia or hyperglyceremia.

Criteria

Inclusion Criteria:

  • We enrolled the patients included age more than 60 years old, no positive finding during dilated fundus examination.

Exclusion Criteria:

  • The exclusion criteria were as followed:

    • systemic disease that will affect visual acuity evaluation (for example: CVA), *opaque cornea and vitreous
    • glaucoma
    • uvietis and other clinically established ocular disease.
  • According to the LOCS III11, those who had nuclear opalescence, nuclear color more than grade 3 or any grade of cortical cataract and posterior subcapsular cataract were also eliminated.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01219478

Locations
Taiwan
Taipei Medical University - WanFang Hospital
Taipei, Taiwan
Sponsors and Collaborators
Taipei Medical University WanFang Hospital
Investigators
Principal Investigator: Hui-Chun Ho Taipei Medical University WanFang Hospital
  More Information

No publications provided

Responsible Party: Hui-Chun Ho, Department of Ophthalmology, Wanfang Hospital
ClinicalTrials.gov Identifier: NCT01219478     History of Changes
Other Study ID Numbers: 99028
Study First Received: October 10, 2010
Last Updated: December 19, 2010
Health Authority: Taiwan: Department of Health

Keywords provided by Taipei Medical University WanFang Hospital:
To investigate the relationship between retinal thickness (RT) and metabolic risks (MRs) in patients without retinal lesion

Additional relevant MeSH terms:
Metabolic Syndrome X
Glucose Metabolism Disorders
Hyperinsulinism
Insulin Resistance
Metabolic Diseases

ClinicalTrials.gov processed this record on November 27, 2014